NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAS-18-915 from the NIH Guide for Grants and Contracts. The National Institutes of Health has recently announced the HIV/AIDS research priorities for the next three to five years https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The goal of this Funding Opportunity Announcement (FOA) is to stimulate high priority research relevant to drug misuse and HIV/AIDS.
Funding Opportunity RFA-CA-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf) Recommendation G (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3 ): "Sponsor initiatives to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing, and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas." This Funding Opportunity Announcement invites U01 applications for projects that develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer so that they can make informed clinical risk management decisions.
Funding Opportunity PAR-18-918 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.
Funding Opportunity PA-18-917 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.
Funding Opportunity PA-18-916 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug misuse and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating drug misuse and/or use disorder and HIV/AIDS across all areas of research supported by NIDA.
Notice NOT-OD-18-230 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-914 from the NIH Guide for Grants and Contracts. The objective of the NIAMS STAR Program is to promote innovation and exploration of high-risk ideas by providing supplemental funding to early established investigators . The STAR Program will support activities that effectively allow these early established investigators to expand and explore new opportunities within the broader scope of a currently funded, peer-reviewed research project to facilitate the transition from a single, structured research project to a research program. For the purpose of this program, NIAMS early established investigators are those who have successfully renewed a first NIAMS-supported R01.
Funding Opportunity PAR-18-913 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Funding Opportunity PAR-18-912 from the NIH Guide for Grants and Contracts. This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications. Areas of Research Collaboration: Applications are encouraged from organization/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collaborations with Indian investigators on the following: diabetic retinopathy, glaucoma, age-related macular degeneration, retinitis pigmentosa, including rare and genetic diseases such as congenital cataracts, as well as other eye conditions such as ocular inflammation/uveitis, refractive error, low vision, and corneal injury. Basic, translational, or epidemiological research maybe proposed. Clinical trials will not be supported under this FOA.
Notice NOT-DA-18-063 from the NIH Guide for Grants and Contracts
Notice NOT-AI-18-059 from the NIH Guide for Grants and Contracts
Notice NOT-MD-18-014 from the NIH Guide for Grants and Contracts
Notice NOT-DA-18-034 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-653 from the NIH Guide for Grants and Contracts
Notice NOT-DE-18-020 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-105 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-106 from the NIH Guide for Grants and Contracts
Notice NOT-MD-18-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.
Funding Opportunity RFA-DA-19-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HAND in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.